ISB

What ISB does

In Silico Biosciences, Inc. (ISB) is a privately held computational neuropharmacology company founded in 2000 and headquartered in Lexington, Massachusetts. The company develops Quantitative Systems Pharmacology (QSP) software, specifically biophysically realistic computer-based mechanistic models of neuronal network circuits calibrated with human imaging and clinical data, to support central nervous system (CNS) drug discovery and development. Its core product, the CNS QSP Platform, simulates complex pathological processes in psychiatric and neurological disorders based on signal processing between different brain regions and is used for target validation, candidate selection, biomarker prediction, dose optimization, clinical trial outcome prediction, and post-marketing pharmacogenomics analysis in Alzheimer's disease, schizophrenia, and Parkinson's disease.

ISB monetizes primarily through professional services and B2B contracts with pharmaceutical R&D decision-makers, with 12 pharmaceutical companies (9 of them in the global top-20) and 3 patient foundations listed as customers. The company also develops the QSPainRelief Prescribing Support Tool, a clinical decision support application that models efficacy and side effects of over 100 analgesics to recommend optimal combination treatments for individual chronic pain patients, distributed through direct clinician subscription. ISB is a founding member of the QSPainRelief Consortium, a five-year, $6M European project with nine academic and industry partners, and holds international patents on its software platform. The company has published over 20 peer-reviewed papers and correctly predicted three clinical trial outcomes prospectively and blindly. It operates with 1-10 employees under founder-CEO Robert Carr.

Name

ISB

Legal name

In Silico Biosciences, Inc.

Website

https://in-silico-biosciences.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

In Silico Biosciences is a privately held computational neuropharmacology firm that builds Quantitative Systems Pharmacology models of neuronal network circuits to support CNS drug discovery for pharmaceutical companies and develops a clinical decision support tool for chronic pain prescribing.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Computational neuroscience modeling
• CNS drug discovery
• Quantitative systems pharmacology
• Chronic pain management
• Clinical decision support

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D

Revenue model

1. Drug Discovery Support Services: ISB provides computer simulation support in drug development for pharmaceutical companies, based on the affinity and pharmacology of new drugs towards human receptors for Alzheimer's disease, Schizophrenia, and Parkinson's disease. Services span preclinical discovery through post-marketing phases.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

In Silico Biosciences (ISB) develops proprietary Quantitative Systems Pharmacology (QSP) software platforms that build biophysically realistic computer-based mechanistic models of neuronal network circuits, calibrated with human imaging and clinical data, to support pharmaceutical drug discovery for CNS disorders (Alzheimer's, schizophrenia, Parkinson's) and chronic pain. The company also provides the QSPainRelief Prescribing Support Tool, a clinical decision support application for clinicians to optimize personalized combination drug therapies for chronic pain patients. Service modules span preclinical discovery, early and late clinical development, and post-marketing phases for pharmaceutical clients.

Product overview

In Silico Biosciences (ISB) offers a unified quantitative systems pharmacology (QSP) platform for CNS drug discovery and chronic pain management. The core product is the CNS Quantitative Systems Pharmacology Platform, a computer-based mechanistic modeling system that simulates biophysically realistic neuronal network circuits calibrated with human imaging and clinical data. This platform is complemented by the QSPainRelief Prescribing Support Tool, a clinical decision support application for clinicians to optimize personalized combination treatments for chronic pain patients. Service modules span preclinical discovery, early and late clinical development, and post-marketing phases. The company has worked with 12 pharmaceutical companies and published over 20 peer-reviewed papers, holding international patents on their software platform.

Differentiator

Problem solved

Functional benefit

Products and services

• CNS Quantitative Systems Pharmacology Platform

Quantifiable outcome

• Correctly predicted three clinical trial outcomes prospectively and blindly
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

One partnership is on record.

• QSPainRelief ConsortiumcoreStrategic or Co-development Partner · 1 January 2020ISB is a founding member of the QSPainRelief Consortium, a five-year, six-million-dollar pharmacological pain relief project. The consortium combines academic and industry leaders in chronic pain, pharmacology, pharmacogenomics, personalized medicine, systems biology, and predictive biophysical computer modeling to develop validated computational models for optimizing personalized treatment of chronic pain. The consortium includes nine European institutions.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Certara: Certara is the leading provider of quantitative systems pharmacology (QSP), pharmacokinetic/pharmacodynamic (PK/PD) modeling, and biosimulation software for the pharmaceutical industry. It is the most direct competitor to ISB in CNS and broader therapeutic QSP services, operating at significantly larger scale.
• Simulations Plus: Simulations Plus provides modeling and simulation software and services for pharmaceutical R&D, including QSP, PBPK, and physiologically-based pharmacokinetic modeling. Like Certara, it is a scaled public competitor in the same computational pharmacology space as ISB, though with broader therapeutic coverage.
• Rosa & Co: Rosa & Co is a specialized QSP and PhysioPD consulting firm that develops computational models to support pharmaceutical R&D decision-making. As a smaller, focused QSP consultancy, it is comparable to ISB in scale, business model, and therapeutic focus.
• Metrum Research Group: Metrum Research Group provides quantitative pharmacology services, including QSP, PK/PD modeling, and clinical pharmacology consulting for pharmaceutical companies. It is comparable to ISB in services-based business model, scientific rigor, and customer base of mid-to-large pharma.
• Physiomics: Physiomics is a computational biology services company that applies mathematical modeling to oncology and other therapeutic areas for pharmaceutical clients. Comparable to ISB in business model (specialist modeling services for pharma) and approach, though with a different primary therapeutic focus.

Emerging players

• GNS Healthcare: GNS Healthcare applies causal AI and machine learning to pharmaceutical R&D and clinical decision support, including drug response prediction and patient stratification. It overlaps with ISB's predictive modeling capabilities but uses different underlying AI/ML methodologies and is at a larger scale.
• InSilico Medicine: InSilico Medicine is an AI-driven drug discovery company that uses deep learning and generative models to identify novel drug targets and molecules. It is comparable to ISB in applying computational/AI methods to CNS and other therapeutic areas, though it operates an internal drug pipeline model rather than a services model.
• Recursion Pharmaceuticals: Recursion applies AI and high-throughput experimental biology to drug discovery, including CNS indications. It is comparable to ISB in the AI-for-drug-discovery space, though it operates an asset-heavy wet-lab + compute platform rather than a pure computational modeling services model.

Broad incumbents

• Schrödinger: Schrödinger is a leading computational chemistry and molecular simulation platform serving pharmaceutical R&D. While it operates at a much larger scale and in a broader chemistry-first domain, it is comparable to ISB in applying physics-based computational methods to drug discovery challenges.
• Evidera (PPD/Thermo Fisher): Evidera, part of PPD/Thermo Fisher Scientific, provides health economics, outcomes research, and real-world evidence services to the pharmaceutical industry. It is comparable to ISB in serving pharma R&D with specialized scientific services, though at vastly greater scale and with broader scope.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/in-silico-biosciences-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ISB